Nymox Pharmaceutical (NYMXF) schedules August 28 shareholder vote on board
Rhea-AI Filing Summary
Nymox Pharmaceutical Corporation, a foreign private issuer, reports that it will hold a Special Shareholder's Meeting on August 28, 2026 to elect the members of its Board of Directors. A Notice of Meeting and a Management Proxy Circular accompany this announcement.
The company also states that its annual report on Form 20-F for the financial year ended December 31, 2025 has been delayed mainly due to previously reported changes in management and the Board, and is planned to be filed with the U.S. Securities and Exchange Commission. Nymox points to its website, www.nymox.com, for current 2026 updates.
Positive
- None.
Negative
- Form 20-F for 2025 delayed due to previously reported management and board changes.
Key Figures
Special shareholder meeting date: August 28, 2026
Financial year-end: December 31, 2025
Report month: August 2026
3 metrics
Special shareholder meeting date
August 28, 2026
Date set for meeting to elect Board of Directors
Financial year-end
December 31, 2025
Year covered by delayed Form 20-F annual report
Report month
August 2026
Month referenced in the Form 6-K report of foreign private issuer
Key Terms
Special Shareholder's Meeting, Management Proxy Circular, Form 20-F, foreign private issuer
4 terms
Management Proxy Circular financial
"see attachments for copies of the Management Proxy Circular"
A management proxy circular is a detailed briefing packet mailed or posted to shareholders before a company meeting that asks them to vote on key matters. It lays out agenda items, background information, management’s recommendations, pay and board candidate details, and instructions for authorizing someone to vote on your behalf. Investors use it like an agenda plus briefing notes to decide how votes could affect who controls the company, its strategy and future returns.
Form 20-F regulatory
"annual report on Form 20-F for the financial year ended"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What is the status of Nymox Pharmaceutical (NYMXF) Form 20-F annual report?
Nymox states that its Form 20-F annual report for the financial year ended December 31, 2025 has been delayed, mainly because of previously reported changes in management and the Board, and is planned to be filed with the U.S. Securities and Exchange Commission.
Why was Nymox Pharmaceutical (NYMXF) Form 20-F filing delayed?
The company explains that its annual report on Form 20-F for the year ended December 31, 2025 was delayed mainly due to previously reported changes in management and the Board, and it indicates that this report is planned to be filed with the SEC.
Where can Nymox Pharmaceutical (NYMXF) investors find 2026 updates and meeting materials?
Nymox directs investors to its website, www.nymox.com, for current 2026 updates. The company also provides a Notice of Meeting and a Management Proxy Circular as exhibits related to the August 28, 2026 special shareholder meeting.